SARM: From immune regulator to cell executioner - PubMed

Review

SARM: From immune regulator to cell executioner

Michael Carty et al. Biochem Pharmacol. 2019 Mar.

Abstract

SARM is the fifth and most conserved member of the Toll/Il-1 Receptor (TIR) adaptor family. However, unlike the other TIR adaptors, MyD88, Mal, TRIF and TRAM, SARM does not participate in transducing signals downstream of TLRs. By contrast SARM inhibits TLR signalling by interacting with the adaptors TRIF and MyD88. In addition, SARM also has positive roles in innate immunity by activating specific transcriptional programs following immune challenge. SARM has a pivotal role in activating different forms of cell death following cellular stress and viral infection. Many of these functions of mammalian SARM are also reflected in SARM orthologues in lower organisms such as C. elegans and Drosophila. SARM expression is particularly enriched in neurons of the CNS and SARM has a critical role in neuronal death and in axon degeneration. Recent fascinating molecular insights have been revealed as to the molecular mechanism of SARM mediated axon degeneration. SARM has been shown to deplete NAD+ by possessing intrinsic NADase activity in the TIR domain of the protein. This activity can be activated experimentally by forced dimerization of the TIR domain. It is thought that this activity of SARM is normally switched off by the axo-protective activities of NMNAT2 which maintain low levels of the NAD+ precursor NMN. Therefore, there is now great excitement in the field of SARM research as targeting this enzymatic activity of SARM may lead to the development of new therapies for neurodegenerative diseases such as multiple sclerosis and motor neuron disease.

Keywords: Amyotrophic lateral sclerosis; Cell death; Innate immunity; NAD+; NADase; Neurodegenerative disease; SARM; Signal transduction; Transcription regulation; Wallerian degeneration.

Similar articles

• SARM modulates MyD88-mediated TLR activation through BB-loop dependent TIR-TIR interactions.

  Carlsson E, Ding JL, Byrne B. Carlsson E, et al. Biochim Biophys Acta. 2016 Feb;1863(2):244-53. doi: 10.1016/j.bbamcr.2015.11.021. Epub 2015 Nov 22. Biochim Biophys Acta. 2016. PMID: 26592460

• The human adaptor SARM negatively regulates adaptor protein TRIF-dependent Toll-like receptor signaling.

  Carty M, Goodbody R, Schröder M, Stack J, Moynagh PN, Bowie AG. Carty M, et al. Nat Immunol. 2006 Oct;7(10):1074-81. doi: 10.1038/ni1382. Epub 2006 Sep 10. Nat Immunol. 2006. PMID: 16964262

• SARM inhibits both TRIF- and MyD88-mediated AP-1 activation.

  Peng J, Yuan Q, Lin B, Panneerselvam P, Wang X, Luan XL, Lim SK, Leung BP, Ho B, Ding JL. Peng J, et al. Eur J Immunol. 2010 Jun;40(6):1738-47. doi: 10.1002/eji.200940034. Eur J Immunol. 2010. PMID: 20306472

• Beyond TLR Signaling—The Role of SARM in Antiviral Immune Defense, Apoptosis & Development.

  Panneerselvam P, Ding JL. Panneerselvam P, et al. Int Rev Immunol. 2015;34(5):432-44. doi: 10.3109/08830185.2015.1065826. Epub 2015 Aug 13. Int Rev Immunol. 2015. PMID: 26268046 Review.

• The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling.

  O'Neill LA, Bowie AG. O'Neill LA, et al. Nat Rev Immunol. 2007 May;7(5):353-64. doi: 10.1038/nri2079. Nat Rev Immunol. 2007. PMID: 17457343 Review.

Cited by

• Genetic ablation of Sarm1 attenuates expression and mislocalization of phosphorylated TDP-43 after mouse repetitive traumatic brain injury.

  Dogan EO, Bouley J, Zhong J, Harkins AL, Keeler AM, Bosco DA, Brown RH Jr, Henninger N. Dogan EO, et al. Acta Neuropathol Commun. 2023 Dec 20;11(1):206. doi: 10.1186/s40478-023-01709-4. Acta Neuropathol Commun. 2023. PMID: 38124145 Free PMC article.

• Drosophila Ectoderm-expressed 4 modulates JAK/STAT pathway and protects flies against Drosophila C virus infection.

  Huang Z, Wang W, Xu P, Gong S, Hu Y, Liu Y, Su F, Anjum KM, Deng WM, Yang S, Liu J, Jiao R, Chen J. Huang Z, et al. Front Immunol. 2023 Feb 3;14:1135625. doi: 10.3389/fimmu.2023.1135625. eCollection 2023. Front Immunol. 2023. PMID: 36817462 Free PMC article.

• Toll/interleukin-1 receptor (TIR) domain-containing proteins have NAD-RNA decapping activity.

  Wang X, Yu D, Yu J, Hu H, Hang R, Amador Z, Chen Q, Chai J, Chen X. Wang X, et al. Nat Commun. 2024 Mar 13;15(1):2261. doi: 10.1038/s41467-024-46499-y. Nat Commun. 2024. PMID: 38480720 Free PMC article.

• A phytobacterial TIR domain effector manipulates NAD⁺ to promote virulence.

  Eastman S, Smith T, Zaydman MA, Kim P, Martinez S, Damaraju N, DiAntonio A, Milbrandt J, Clemente TE, Alfano JR, Guo M. Eastman S, et al. New Phytol. 2022 Jan;233(2):890-904. doi: 10.1111/nph.17805. Epub 2021 Nov 5. New Phytol. 2022. PMID: 34657283 Free PMC article.

• Interaction of antiphospholipid antibodies with endothelial cells in antiphospholipid syndrome.

  Feng W, Qiao J, Tan Y, Liu Q, Wang Q, Yang B, Yang S, Cui L. Feng W, et al. Front Immunol. 2024 Jul 9;15:1361519. doi: 10.3389/fimmu.2024.1361519. eCollection 2024. Front Immunol. 2024. PMID: 39044818 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database

• Molecular Biology Databases

  • FlyBase

• Research Materials

  • NCI CPTC Antibody Characterization Program